Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 3
1996 1
1997 2
1998 17
1999 49
2000 61
2001 165
2002 295
2003 356
2004 495
2005 599
2006 610
2007 725
2008 710
2009 684
2010 716
2011 672
2012 720
2013 727
2014 729
2015 672
2016 722
2017 683
2018 651
2019 628
2020 689
2021 616
2022 556
2023 483
2024 419
2025 185

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,750 results

Results by year

Filters applied: . Clear all
Page 1
Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.
Saadoun D, Maalouf G, Vieira M, Trad S, Lazaro E, Sacre K, Plessier A, Sené T, Koné-Paut I, Noel N, Mekinian A, Lambert M, Ribeiro E, Mirault T, Mele N, Dellal A, Fain O, Melki I, Chiche L, Gaudric J, Redheuil A, Maillart E, Ghembaza A, Desbois AC, Mirouse A, Domont F, Leroux G, Ferfar Y, Rigolet A, Viallard JF, Vautier M, Resche-Rigon M, Cacoub P. Saadoun D, et al. NEJM Evid. 2024 Nov;3(11):EVIDoa2300354. doi: 10.1056/EVIDoa2300354. Epub 2024 Oct 22. NEJM Evid. 2024. PMID: 39437137 Clinical Trial.
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial.
Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell WR, Wright EK, Taylor KM, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith G, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, De Cruz P. Choy MC, et al. Lancet Gastroenterol Hepatol. 2024 Nov;9(11):981-996. doi: 10.1016/S2468-1253(24)00200-0. Epub 2024 Sep 2. Lancet Gastroenterol Hepatol. 2024. PMID: 39236736 Clinical Trial.
Behçet's syndrome: one year in review 2023.
Hatemi G, Seyahi E, Fresko I, Talarico R, Uçar D, Hamuryudan V. Hatemi G, et al. Clin Exp Rheumatol. 2023 Oct;41(10):1945-1954. doi: 10.55563/clinexprheumatol/7kdo9x. Epub 2023 Oct 10. Clin Exp Rheumatol. 2023. PMID: 37877363 Free article. Review.
Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease.
Griffin H, Ceron-Gutierrez L, Gharahdaghi N, Ebrahimi S, Davies S, Loo PS, Szabo A, Williams E, Mukhopadhyay A, McLoughlin L, Irwin S, Travis S, Klenerman P, Bunn S, Cant AJ, Hambleton S, Uhlig HH, Doffinger R. Griffin H, et al. N Engl J Med. 2024 Aug 1;391(5):434-441. doi: 10.1056/NEJMoa2312302. N Engl J Med. 2024. PMID: 39083772 Free PMC article.
Efficacy and safety of infliximab in patients with autoimmune hepatitis.
Efe C, Lytvyak E, Eşkazan T, Liberal R, Androutsakos T, Turan Gökçe D, Terziroli Beretta-Piccoli B, Janik M, Bernsmeier C, Arvaniti P, Milkiewicz P, Batibay E, Yüksekyayla O, Ergenç I, Arikan Ç, Stättermayer AF, Barutçu S, Cengiz M, Gül Ö, Heurgue A, Heneghan MA, Verma S, Purnak T, Törüner M, Akdogan Kayhan M, Hatemi I, Zachou K, Macedo G, Drenth JPH, Björnsson E, Montano-Loza AJ, Wahlin S, Higuera-de la Tijera F. Efe C, et al. Hepatology. 2025 Jun 1;81(6):1660-1670. doi: 10.1097/HEP.0000000000001089. Epub 2024 Sep 6. Hepatology. 2025. PMID: 39250458
SB2: An Infliximab Biosimilar.
Lamb YN, Scott LJ, Deeks ED. Lamb YN, et al. BioDrugs. 2017 Oct;31(5):461-464. doi: 10.1007/s40259-017-0240-7. BioDrugs. 2017. PMID: 28803431 Review.
12,750 results
You have reached the last available page of results. Please see the User Guide for more information.